Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier

(2017) Masahiro Seike et al.   ONCOLOGY REPORTS

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

(2017) Ken Uchibori et al.   Nature Communications

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells

(2016) NOBUHIKO NISHIJIMA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Scientific Advances in Lung Cancer 2015

(2016) Anne S. Tsao et al.   Journal of Thoracic Oncology

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial–mesenchymal transition and invasion in mice and humans

(2016) L Zhang et al.   ONCOGENE

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

(2015) T. Sugano et al.   MOLECULAR CANCER THERAPEUTICS

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer

(2015) Mariko Kikuchi et al.   Oncotarget

Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth

(2015) Akiko Takahashi et al.   Oncotarget

Induction of Ankrd1 in Dilated Cardiomyopathy Correlates with the Heart Failure Progression

(2015) Julius Bogomolovas et al.   Biomed Research International

Nestin regulates proliferation, migration, invasion and stemness of lung adenocarcinoma

(2014) KOSUKE NARITA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis

(2014) Y Lei et al.   ONCOGENE

DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1

(2014) E-J Yun et al.   ONCOGENE

Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung

(2013) Akiko Takahashi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

MiR-134/487b/655 Cluster Regulates TGF- -Induced Epithelial-Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells

(2013) K. Kitamura et al.   MOLECULAR CANCER THERAPEUTICS

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

A novel role for cardiac ankyrin repeat protein Ankrd1/CARP as a co-activator of the p53 tumor suppressor protein

(2010) Snezana Kojic et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers

(2009) M. Seike et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer

(2008) L. L. Scurr et al.   CLINICAL CANCER RESEARCH

Expression of cardiac ankyrin repeat protein, CARP, in malignant tumors: diagnostic use of CARP protein immunostaining in rhabdomyosarcoma

(2008) Naoko Ishiguro et al.   HUMAN PATHOLOGY